IP Library Granted Patent US 7,229,413
Granted Patent B2
US 7,229,413 · App. 10/647,119 · Granted Jun 12, 2007

Echogenic coatings with overcoat

Assignee: Angiotech Biocoatings Corp.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,229,413
App. No.
10/647,119
Granted
Jun 12, 2007
Kind
B2
Abstract

An ultrasonically visible solid device for inserting into a non-gas target medium comprises an echogenic surface having structures entrapping gas when the device is in the target medium, the entrapped gas causing the device to be ultrasonically visible, wherein the gas-entrapping structures are covered with a flexible overcoat that does not significantly reduce the compressibility of the gas trapped in the structures.

Claims (42)

1. An ultrasonically visible solid device for inserting into a non-gas target medium, the device comprising an echogenic surface having structures entrapping gas causing the device to be ultrasonically visible, wherein the gas-entrapping structures are formed from open structures covered with a flexible overcoat layer that does not significantly reduce the compressibility of the gas trapped in the structures, and wherein the overcoat layer has a flexural modulus greater than about 500 psi.

2. A device according to claim 1 , wherein the structures are selected from the group consisting of pores, channels, cavities, pockets, and combinations thereof, covered by the overcoat.

3. A device according to claim 1 , wherein the overcoat incorporates one or more pharmaceutical agents.

4. A device according to claim 1 , wherein the overcoat layer reduces wettability so as to promote and/or prolong the entrapment of gas when the device is in the target medium.

5. A device according to claim 1 , wherein the overcoat layer has a thickness below about 2 microns.

6. A device according to claim 1 , wherein the overcoat layer has a thickness of between about 0.1 and about 1 micron.

7. A device according to claim 1 , comprising one or more of a pharmaceutical agent selected from the group consisting of anti-thrombogenic agents, anti-inflammatory agents, antineoplastic agents, anti-proliferative agents, cytostatic agents, cytotoxic agents, antimicrobial agents, anti-restenotic agents, anti-platelet agents, anti-coagulant agents, anti-fibrin and fibrinolytic agents, prostacyclins (and analogues), glycoprotein IIb/IIIa agents, thromboxane inhibitors, anti-thrombin agents, anti-mitotic, antiangiogenic and angiostatic agents, ACE inhibitors, growth factor antagonists, antioxidants, vitamins, calcium channel blockers, fish oil (omega 3-fatty acid), phosphodiesterase inhibitors, nitric acid donor, Somatostatin analogues, immunosuppresives and antiinflamatory agents, antimicrobials, radionuclides including alpha, beta and gamma emitting isotopes, COX-2 inhibitors, endothelial promoters, kinase inhibitors, epidermal growth factor kinase inhibitors, tyrosine kinase inhibitors, MAP kinase inhibitors, and protein transferase inhibitors.

8. A device according to claim 1 , comprising comprises one or more of a pharmaceutical agent selected from the group consisting of plasmin, streptokinase, single chain urokinase, urokinase, t-PA (tissue type plasminogen activator), aminocaproic acid, aspirin, monoclonal antibodies, peptides, ReoPro, Cilastagel, eptifibatide, tirofiban, ticlopidine, Vapiprost, dipyridamole, forskolin, angiopeptin, argatroban, dextan, heparin, LMW heparin, Enoxaparin, Dalteparin, hirudin, recombinant hirudin, anti-thrombin, synthetic antithrombins, thrombin inhibitors, Warfarin, other coumarins, vincristine, vinblastine, paclitaxel and its analogues, methotrexate, cisplatin, fluorouracil, rapamycin, azathioprine, cyclophosphamide, mycophenolic acid, corticosteroids, colchicine, nitroprusside, angiostatin and endostatin; genetic materials, oligonucleotides, Cilazapril, Lisinopril, Captopril, VEGF, FGF, Probucol, Tocopherol, nifedipine, Molsidomine, angiopeptin, prednisolone, glucocorticoid, dexamethasone, rifamycin, Re-188, Re-186, I-125, Y-90 celecoxib, Vioxx, and theophylline.

9. A device according to claim 1 , wherein the device is a stent, central venous catheter, peripherally inserted catheter, graft, shunt, percutaneous transcardiac arterial catheter, pacemaker, dialysis device, joint replacement, long term urinary device, tissue bonding urinary device, penile prosthesis, vascular catheter port, peripherally insertable central venous catheter, long term tunneled central venous catheter, peripheral venous catheter, short term central venous catheter, arterial catheter, PCTA or PTA catheter, and pulmonary artery Swan-Ganz catheter, guidewire, a surgical instrument, endoscopy equipment, an angioplasty balloon, a wound drain, a gastroenteric tube, laparoscopy equipment, a pellet, and an implant, a needle, a biopsy needle, and combinations thereof.

10. An ultrasonically visible solid device for inserting into a non-gas target medium, the device comprising an echogenic surface having structures entrapping gas causing the device to be ultrasonically visible, wherein the gas-entrapping structures are formed from open structures covered with a flexible overcoat layer that does not significantly reduce the compressibility of the gas trapped in the structures, and wherein the overcoat layer has an elongation at break greater than about 100 percent.

11. A device according to claim 10 , wherein the structures are selected from the group consisting of pores, channels, cavities, pockets, and combinations thereof, covered by the overcoat.

12. A device according to claim 10 , wherein the overcoat incorporates one or more pharmaceutical agents.

13. A device according to claim 10 , wherein the overcoat layer reduces wettability so as to promote and/or prolong the entrapment of gas when the device is in the target medium.

14. A device according to claim 10 , wherein the overcoat layer has a thickness below about 2 microns.

15. A device according to claim 10 , wherein the overcoat layer has a thickness of between about 0.1 and about 1 micron.

16. A device according to claim 10 , comprising one or more of a pharmaceutical agent selected from the group consisting of anti-thrombogenic agents, anti-inflammatory agents, antineoplastic agents, anti-proliferative agents, cytostatic agents, cytotoxic agents, antimicrobial agents, anti-restenotic agents, anti-platelet agents, anti-coagulant agents, anti-fibrin and fibrinolytic agents, prostacyclins (and analogues), glycoprotein IIb/IIIa agents, thromboxane inhibitors, anti-thrombin agents, anti-mitotic, antiangiogenic and angiostatic agents, ACE inhibitors, growth factor antagonists, antioxidants, vitamins, calcium channel blockers, fish oil (omega 3-fatty acid), phosphodiesterase inhibitors, nitric acid donor, Somatostatin analogues, immunosuppresives and antiinflamatory agents, antimicrobials, radionuclides including alpha, beta and gamma emitting isotopes, COX-2 inhibitors, endothelial promoters, kinase inhibitors, epidermal growth factor kinase inhibitors, tyrosine kinase inhibitors, MAP kinase inhibitors, and protein transferase inhibitors.

17. A device according to claim 10 , comprising comprises one or more of a pharmaceutical agent selected from the group consisting of plasmin, streptokinase, single chain urokinase, urokinase, t-PA (tissue type plasminogen activator), aminocaproic acid, aspirin, monoclonal antibodies, peptides, ReoPro, Cilastagel, eptifibatide, tirofiban, ticlopidine, Vapiprost, dipyridamole, forskolin, angiopeptin, argatroban, dextan, heparin, LMW heparin, Enoxaparin, Dalteparin, hirudin, recombinant hirudin, anti-thrombin, synthetic antithrombins, thrombin inhibitors, Warfarin, other coumarins, vincristine, vinblastine, paclitaxel and its analogues, methotrexate, cisplatin, fluorouracil, rapamycin, azathioprine, cyclophosphamide, mycophenolic acid, corticosteroids, colchicine, nitroprusside, angiostatin and endostatin; genetic materials, oligonucleotides, Cilazapril, Lisinopril, Captopril, VEGF, FGF, Probucol, Tocopherol, nifedipine, Molsidomine, angiopeptin, prednisolone, glucocorticoid, dexamethasone, rifamycin, Re-188, Re-186, I-125, Y-90 celecoxib, Vioxx, and theophylline.

18. A device according to claim 10 , wherein the device is a stent, central venous catheter, peripherally inserted catheter, graft, shunt, percutaneous transcardiac arterial catheter, pacemaker, dialysis device, joint replacement, long term urinary device, tissue bonding urinary device, penile prosthesis, vascular catheter port, peripherally insertable central venous catheter, long term tunneled central venous catheter, peripheral venous catheter, short term central venous catheter, arterial catheter, PCTA or PTA catheter, and pulmonary artery Swan-Ganz catheter, guidewire, a surgical instrument, endoscopy equipment, an angioplasty balloon, a wound drain, a gastroenteric tube, laparoscopy equipment, a pellet, and an implant, a needle, a biopsy needle, and combinations thereof.

19. An ultrasonically visible solid device for inserting into a non-gas target medium, the device comprising an echogenic surface having structures entrapping gas causing the device to be ultrasonically visible, wherein the gas-entrapping structures are formed from open structures covered with a flexible overcoat layer that does not significantly reduce the compressibility of the gas trapped in the structures, and wherein the overcoat layer has a water permeability of less than about 10 −10 [(cm 3 )(cm)]/(cm 2 )(s)(cm Hg)].

20. The device of claim 19 , wherein the overcoat improves one or more properties of the device selected from echogenic coating durability, lubricity, surface smoothness, protection of the echogenic layer from deleterious effects of exposure to body fluids.

21. The device of claim 19 , wherein the structures are selected from the group consisting of pores, channels, cavities, pockets, and combinations thereof, covered by the overcoat.

22. The device of claim 19 , wherein the overcoat incorporates one or more pharmaceutical agents.

23. The device of claim 19 , wherein the overcoat layer reduces wettability so as to promote and/or prolong the entrapment of gas when the device is in the target medium.

24. A device according to claim 19 , wherein the overcoat layer has a thickness below about 2 microns.

25. A device according to claim 19 , wherein the overcoat layer has a thickness of between about 0.1 and about 1 micron.

26. A device according to claim 19 , wherein the overcoat layer results in a decrease in the compressibility of less than about 20 percent of the entrapped gas.

27. A device according to claim 19 , wherein the device is a stent, central venous catheter, peripherally inserted catheter, graft, shunt, percutaneous transcardiac arterial catheter, pacemaker, dialysis device, joint replacement, long term urinary device, tissue bonding urinary device, penile prosthesis, vascular catheter port, peripherally insertable central venous catheter, long term tunneled central venous catheter, peripheral venous catheter, short term central venous catheter, arterial catheter, PCTA or PTA catheter, and pulmonary artery Swan-Ganz catheter, guidewire, a surgical instrument, endoscopy equipment, an angioplasty balloon, a wound drain, a gastroenteric tube, laparoscopy equipment, a pellet, and an implant, a needle and combinations thereof.

28. A device according to claim 27 , wherein the needle is a biopsy needle.

29. The device of claim 19 , wherein the overcoat comprises one or more of polyethylene, ethylene/vinyl acetate copolymers, epoxy resins, polydimethylsiloxane, polytetrafluoroethylene, polyvinylbutyral, polyvinylidinechloride, polyurethanes, polyimides, rubbers, acrylate polymers/copolymers, butadiene, styrene butadiene, and styrene butadiene/styrene copolymers.

30. The device of claim 19 , comprising an active agent selected from one or more of anti-thrombogenic agents, anti-inflammatory agents, antineoplastic agents, anti-proliferative agents, cytostatic agents, cytotoxic agents, antimicrobial agents, anti-restenotic agents, anti-platelet agents, anti-coagulant agents, anti-fibrin and fibrinolytic agents, prostacyclins (and analogues), glycoprotein IIb/IIIa agents, thromboxane inhibitors, anti-thrombin agents, anti-mitotic, antiangiogenic and angiostatic agents, ACE inhibitors, growth factor antagonists, antioxidants, vitamins, calcium channel blockers, fish oil (omega 3-fatty acid), phosphodiesterase inhibitors, nitric acid donor, Somatostatin analogues, immunosuppresives and antiinflamatory agents, antimicrobials, radionuclides including alpha, beta and gamma emitting isotopes, COX-2 inhibitors, endothelial promoters, kinase inhibitors, epidermal growth factor kinase inhibitors, tyrosine kinase inhibitors, MAP kinase inhibitors, and protein transferase inhibitors.

31. The device of claim 19 , comprising an active agent selected from one or more of plasmin, streptokinase, single chain urokinase, urokinase, t-PA (tissue type plasminogen activator), aminocaproic acid, aspirin, monoclonal antibodies, peptides, ReoPro, Cilastagel, eptifibatide, tirofiban, ticlopidine, Vapiprost, dipyridamole, forskolin, angiopeptin, argatroban, dextan, heparin, LMW heparin, Enoxaparin, Dalteparin, hirudin, recombinant hirudin, anti-thrombin, synthetic antithrombins, thrombin inhibitors, Warfarin, other coumarins, vincristine, vinblastine, paclitaxel and its analogues, methotrexate, cisplatin, fluorouracil, rapamycin, azathioprine, cyclophosphamide, mycophenolic acid, corticosteroids, colchicine, nitroprusside, angiostatin and endostatin; genetic materials, oligonucleotides, Cilazapril, Lisinopril, Captopril, VEGF, FGF, Probucol, Tocopherol, nifedipine, Molsidomine, angiopeptin, prednisolone, glucocorticoid, dexamethasone, rifamycin, Re-188, Re-186, I-125, Y-90 celecoxib, Vioxx, and theophylline.

32. A method of making the device of claim 19 , comprising preparing a surface having open gas-trapping structures, and over-coating with a thin, flexible film enclosing the entrapped gas in the surface structures beneath the coating.

33. A method of visualizing a medical device according to claim 19 , in an ambient medium, comprising:

inserting the device into a tissue,

leaving the device in the tissue for a prolonged period,

then directing an ultrasound beam at the tissue, and observing the device in the tissue.

34. A method for increasing the echogenicity of an object when subjected to ultrasound in an ambient material, the method comprising the steps of:

providing a coating liquid comprising a film-forming constituent;

applying the coating liquid to the object;

allowing the film-forming constituent to form a film comprising a solid matrix; and

providing the film with an echogenic structure presenting echogenicity-increasing gas/non-gas interfaces,

wherein the echogenic structure comprises a top coating over gas-trapping spaces, the top coating having a water permeability of less than about 10 −10 [(cm 3 )(cm)]/(cm 2 )(s)(cm Hg)], and wherein providing the film with an echogenic structure comprises including in the coating liquid (a) gas bubbles, and/or (b) a reactive material that generates gas upon reaction with a reactor and further contacting the reactive material with the reactor to produce gas.

Assignments (16)
RELEASE OF SECURITY INTEREST Recorded May 7, 2019
From: VIRTUS GROUP, LP, AS ADMINISTRATIVE AGENT FOR THE LENDERS
To: SURGICAL SPECIALTIES CORPORATION LIMITED
Reel/Frame 049106/0173 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE ADDRESS PREVIOUSLY RECORDED ON REEL 042115 FRAME 0140. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Aug 8, 2017
From: ANGIOTECH PHARMACEUTICALS, INC.
To: SURGICAL SPECIALTIES CORPORATION LIMITED
Reel/Frame 043332/0360 →
PARTIAL RELEASE OF SECURITY INTEREST Recorded Apr 5, 2017
From: VIRTUS GROUP, LP
To: ANGIOTECH PHARMACEUTICALS, INC.
Reel/Frame 042166/0029 →
SECURITY INTEREST Recorded Apr 5, 2017
From: SURGICAL SPECIALTIES CORPORATION LIMITED
To: VIRTUS GROUP, LP
Reel/Frame 041860/0980 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 28, 2017
From: ANGIOTECH PHARMACEUTICALS, INC.
To: SURGICAL SPECIALTIES CORPORATION LIMITED
Reel/Frame 042115/0140 →
SECURITY INTEREST Recorded Mar 10, 2017
From: ANGIOTECH PHARMACEUTICALS, INC.
To: VIRTUS GROUP, LP
Reel/Frame 041539/0864 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 26, 2014
From: ANGIOTECH BIOCOATINGS CORP.
To: ANGIOTECH PHARMACEUTICALS (US), INC.
Reel/Frame 034034/0900 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 29, 2013
From: ANGIOTECH PHARMACEUTICALS (US), INC.
To: ANGIOTECH PHARMACEUTICALS, INC.
Reel/Frame 031510/0399 →
RELEASE OF SECURITY INTEREST Recorded Apr 15, 2013
From: DEUTSCHE BANK NATIONAL TRUST COMPANY
To: ANGIOTECH PHARMACEUTICALS, INC.; AMERICAN MEDICAL INSTRUMENTS HOLDINGS, INC.; ANGIOTECH AMERICA, INC.; ANGIOTECH BIOCOATINGS CORP.; ANGIOTECH PHARMACEUTICALS (US), INC.; B.G. SULZLE, INC.; MANAN MEDICAL PRODUCTS, INC.; MEDICAL DEVICE TECHNOLOGIES, INC.; QUILL MEDICAL, INC.; SURGICAL SPECIALTIES CORPORATION; ANGIOTECH INTERNATIONAL HOLDINGS CORP.
Reel/Frame 030218/0820 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2013
From: ANGIOTECH BIOCOATINGS CORP.
To: ANGIOTECH PHARMACEUTICALS (US), INC.
Reel/Frame 029930/0255 →
SECURITY AGREEMENT Recorded Mar 2, 2009
From: ANGIOTECH PHARMACEUTICALS, INC.; AFMEDICA, INC.; AMERICAN MEDICAL INSTRUMENTS HOLDINGS, INC.; ANGIOTECH AMERICA, INC.; ANGIOTECH BIOCOATINGS CORP.; ANGIOTECH CAPITAL, LLC; ANGIOTECH PHARMACEUTICALS (US), INC.; B.G. SULZLE, INC.; CRIMSON CARDINAL CAPITAL, LLC; MANAN MEDICAL PRODUCTS, INC.; MEDICAL DEVICE TECHNOLOGIES, INC.; NEUCOLL INC.; QUILL MEDICAL, INC.; SURGICAL SPECIALTIES CORPORATION; 0741693 BRITISH COLUMBIA LTD.; 3091796 NOVA SCOTIA COMPANY; ANGIOTECH INTERNATIONAL HOLDINGS, CORP.; ANGIOTECH INVESTMENT PARTNERSHIP
To: WELLS FARGO FOOTHILL, LLC AS AGENT
Reel/Frame 022329/0310 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME PREVIOUSLY RECORDED ON REEL 018606 FRAME 0632. ASSIGNOR(S) HEREBY CONFIRMS THE RELEASE OF SECURITY INTEREST. Recorded Dec 14, 2006
From: CREDIT SUISSE
To: ANGIOTECH BIOCOATINGS CORP.
Reel/Frame 018633/0599 →
RELEASE OF SECURITY INTEREST Recorded Dec 11, 2006
From: CREDIT SUISSE
To: ANGIOTECH BIOCOATINGS, INC.
Reel/Frame 018606/0632 →
SECURITY AGREEMENT Recorded Apr 11, 2006
From: ANGIOTECH BIOCOATINGS CORP.
To: CREDIT SUISSE, AS COLLATERAL AGENT
Reel/Frame 017448/0708 →
CHANGE OF NAME Recorded Jan 3, 2005
From: STS BIOPOLYMERS, INC.
To: ANGIOTECH BIOCOATINGS CORP.
Reel/Frame 016116/0127 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 25, 2003
From: VIOLANTE, MICHAEL R.; WHITBOURNE, RICHARD J.; LANZAFAME, JOHN F.; LYDON, MARGARET
To: STS BIOPOLYMERS, INC.
Reel/Frame 014747/0502 →
Continuity (4)
Continuation In Part 0936619300 · Aug 4, 1999
Continuation 0896539300 · Nov 6, 1997
Provisional Application 6003404500 · Nov 6, 1996
Related Publication 20040077948A1 · Apr 22, 2004